Legislation threatens patent protections and future innovation
Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant more requests to institute administrative patent trials. Not only would the RAIA prohibit the PTAB from deferring to federal courts when th ere is an imminent district court trial that would resolve the issues, it would encourage federal courts not to move forward with trials. This would reduce the power of the federal district courts and elevate the PTAB over presidentially-appointed federal judges. (Source: The Catalyst)
Source: The Catalyst - January 12, 2022 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Patents Intellectual Property Source Type: news
New study finds more than half of brand medicine spending goes to the supply chain and others
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to anew analysis from the Berkeley Research Group (BRG). These new findings help illuminate the problems that exist throughout the health care system and why holistic, patient-centered solutions are needed to make medicines more affordable for patients. (Source: The Catalyst)
Source: The Catalyst - January 7, 2022 Category: Pharmaceuticals Authors: Brian Newell Tags: Drug Cost 340B Out-of-Pocket Costs Policy Solutions Proactive Agenda Source Type: news
New NHE data show the true picture of health care spending
Last week, the Centers for Medicare& Medicaid Services (CMS) releasedNational Health Expenditures (NHE) data that show net prices for retail prescription medicines declined, on average, by 0.1% in 2020. The latest facts on health care spending also show that total retail prescription drug spending grew at a modest 3.0% in 2020, below the previous year ’s growth. The data, which also look at spending on other health sectors, further reiterate why policymakers need to look across the entire health care system when looking to lower health care spending: (Source: The Catalyst)
Source: The Catalyst - December 22, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Drug Cost Source Type: news
Making medicines more affordable: Preserving safety-net programs like 340B
Common-sense reforms can help ensure everyone benefits from America ’s engine of innovation and receives the care they need and deserve. In thisseries, we ’re taking a closer look at PhRMA’s advocacy efforts to make medicines more affordable, part of ourpatient-centered agenda, which aims to lower barriers between our industry’s medical innovations and patients who need them. (Source: The Catalyst)
Source: The Catalyst - December 17, 2021 Category: Pharmaceuticals Authors: Emilie Signora Tags: 340B Policy Solutions Proactive Agenda Source Type: news
Post-approval research save lives. Why is Congress trying disincentivize it?
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new authority to set prices for medicines in Medicare after a product has been on the market for 7 (small molecule drugs) or 11 (biologics) years. (Source: The Catalyst)
Source: The Catalyst - December 17, 2021 Category: Pharmaceuticals Tags: Part D Medicare Part B Policy Solutions Voters for Cures Proactive Agenda Source Type: news
New Report: Nearly 800 new medicines in development to treat rare diseases
Today, PhRMA released anew report detailing orphan drug development in the U.S. and the potential to meet the significant unmet medical need for patients. Rare diseases and conditions individually affect small patient populations, but collectively they impact approximately 400 million patients around the world. America ’s biopharmaceutical research companies have spent decades working to tackle these extremely challenging diseases, of which researchers have identified approximately 8,000. In the United States alone, roughly 30 million Americans are living with a rare disease. (Source: The Catalyst)
Source: The Catalyst - December 16, 2021 Category: Pharmaceuticals Tags: Medicines in Development Research and Development Rare Diseases Source Type: news
A price control by any other name would still put patients at risk and threaten innovation
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the government to dictate medicine prices. (Source: The Catalyst)
Source: The Catalyst - December 9, 2021 Category: Pharmaceuticals Tags: Part D Medicare Part B Policy Solutions Proactive Agenda Source Type: news
Making medicines more affordable: Making insurance work like insurance
Common-sense reforms can help ensure everyone benefits from America ’s engine of innovation and receives the care they need and deserve. In thisseries, we ’re taking a closer look at PhRMA’s advocacy efforts to make medicines more affordable, part of ourpatient-centered agenda, which aims to lower barriers between our industry’s medical innovations and patients who need them. (Source: The Catalyst)
Source: The Catalyst - December 8, 2021 Category: Pharmaceuticals Authors: Emilie Signora Tags: Medicare Out-of-Pocket Costs Policy Solutions Proactive Agenda Source Type: news
Recap: Our inaugural graduate summit and career expo
On October 27 and 28, 2021, PhRMA held our inaugural graduate summit and career expo, Pathways to Success in Biopharma. As part of a joint partnership between PhRMA,CHI,UNCF and theErnest E. Just Life Science Society, the virtual summit connected students with many of today ’s leading biopharmaceutical companies. (Source: The Catalyst)
Source: The Catalyst - December 8, 2021 Category: Pharmaceuticals Authors: Dr. Steven Thomas Tags: Research and Development Equity Source Type: news
New report details the promise of the biopharmaceutical pipeline
The biopharmaceutical pipeline contains thousands of innovative new treatments that have the potential to address unmet medical needs, save lives and improve patients ’ health. A new report by the Analysis Group, “Innovation in the Biopharmaceutical Pipeline, ” examines the drug development pipeline and shines a light on the innovations researchers are currently pursuing (Source: The Catalyst)
Source: The Catalyst - December 7, 2021 Category: Pharmaceuticals Authors: Abigail Lore Tags: Research and Development Source Type: news
Navigating the patient experience in the time of COVID-19
According to our inauguralPatient Experience Survey, the pandemic has created new access and affordability barriers to care, exacerbating the health care concerns of Americans and their families.For many Americans, direct impacts from the pandemic, including loss of income or loss of employer-sponsored health insurance coverage, have brought barriers in health care access and affordability to the forefront. (Source: The Catalyst)
Source: The Catalyst - December 6, 2021 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Policy Solutions Coronavirus Polling Source Type: news
3 things to know about the importance of post-approval research and development
Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn ’t stop at U.S. Food and Drug Administration (FDA) approval. After approval, scientists and physicians continue to generate information on a new medicine or vaccine, as we’re seeing with COVID-19 vaccines today. This is done both for approved indications and to develop the medicine potentially f or new, supplemental indications treating important unmet medical needs. (Source: The Catalyst)
Source: The Catalyst - December 6, 2021 Category: Pharmaceuticals Tags: Research and Development Drug Cost Medicare Pediatrics Proactive Agenda Source Type: news
New data show insurers and PBMs increase barriers to care
New data show insurers and middlemen known as pharmacy benefit managers (PBMs) are making it harder for patients to get the medicines they need. (Source: The Catalyst)
Source: The Catalyst - December 2, 2021 Category: Pharmaceuticals Authors: Katie Koziara Tags: Affordable Care Act Part D Source Type: news
World AIDS Day: Remembering those we ’ve lost and exploring the continued fight against HIV/AIDS
Today, as we mark World AIDS Day and commemorate those who lost their lives to AIDS-related illnesses, we want to recognize the impressive advancements in HIV/AIDS scientific research and drug development that have taken place over the past four decades. These innovations in disease prevention, management and treatment have led to dramatic declines in death rates, allowing those living with HIV/AIDS to enjoy longer, fuller lives. (Source: The Catalyst)
Source: The Catalyst - December 1, 2021 Category: Pharmaceuticals Tags: Research and Development HIV/AIDS PDUFA Source Type: news
Global COVID-19 vaccination matters now and for the future
Recently, I joined a panel at the Aspen Security Forum to discuss how we can best get vaccines in arms around the globe as we fight COVID-19. As I noted during my remarks, the world is more interconnected than ever before, which means that combating theCOVID-19 pandemic can only be successful with effective international cooperation. One of the most important goals of that cooperation is equitable global vaccine distribution. We have to avoid nationalist, protectionist policies that would create inequities, leaving parts of the world substantially under-vaccinated, and limit our ability to slow COVID-19 infections around t...
Source: The Catalyst - November 29, 2021 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Intellectual Property Vaccines Coronavirus Supply Chain Source Type: news
